PURPOSE The aim of this study was to analyse the influence of age on the treatment outcome and toxicity in patients with T1HG non-muscle invasive bladder cancers treated with BCG immunotherapy. METHODS Data from 637 patients with primary T1HG bladder cancer who were treated between 1986 and 2016 in two academic centres were retrospectively reviewed. Median follow-up was 57 months. Patients were divided into two groups: younger (< 70 years old) and older (≥ 70 years old). Additional analyses in subgroups of older (> 75 and > 80) patients were performed. Log-rank test, Cox regression analysis, and propensity score matching were performed to compare the groups. RESULTS There were 389 patients below and 248 patients above or equal 70 years old. Recurrence-free, progression-free, and cancer-specific survival rates did not differ significantly between younger and older patients. Recurrence-free survival for younger and older patients were 55.4% vs 52.9%, progression-free survival 75.9% vs 76.6%, and cancer-specific survival were 87.5% vs 89.9% (all p > 0.05). Differences in the oldest subgroups also did not reach statistical significance. In both regression analysis and propensity score matching, no statistically significant associations of age with any of analysed end-points were found. Finally, there were no statistically significant differences between younger and older group in terms of moderate and severe complications occurrence (47.6% vs. 44.5%; p > 0.05) CONCLUSIONS: It was shown that increasing age was not associated with BCG immunotherapy oncological outcomes, or with BCG toxicity in T1HG non-muscle invasive bladder cancer.

中文翻译：

---

年龄对卡介苗免疫治疗非肌层浸润性膀胱癌肿瘤学结果和毒性的影响分析。

目的 本研究的目的是分析年龄对接受 BCG 免疫治疗的 T1HG 非肌肉浸润性膀胱癌患者的治疗结果和毒性的影响。方法对 1986 年至 2016 年间在两个学术中心接受治疗的 637 例原发性 T1HG 膀胱癌患者的数据进行回顾性分析。中位随访时间为 57 个月。患者分为两组：年轻（< 70 岁）和老年（≥ 70 岁）。对老年（> 75 和> 80）患者的亚组进行了额外的分析。进行对数秩检验、Cox 回归分析和倾向评分匹配以比较各组。结果70岁以下389例，70岁以上248例。无复发，无进展，年轻和老年患者的癌症特异性生存率没有显着差异。年轻和老年患者的无复发生存率为 55.4% vs 52.9%，无进展生存率为 75.9% vs 76.6%，癌症特异性生存率为 87.5% vs 89.9%（所有 p > 0.05）。最老的亚组之间的差异也没有达到统计学意义。在回归分析和倾向评分匹配中，没有发现年龄与任何分析终点的统计学显着关联。最后，在中度和重度并发症发生率方面，年轻组和老年组之间没有统计学上的显着差异（47.6% vs. 44.5%；p > 0.05）